Skip to main content
Equibles
COCP logo

COCP · Cocrystal Pharma, Inc.

Track COCP — free

Use COCP with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about COCP

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.09 -0.03 (-2.68%) At close · Aug 17
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“For the six months ended June 30, 2026, the Company recorded a net loss of approximately $5,463 and used approximately $4,856 of cash in operating activities. These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$21.38M
Shares
19.26M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.09 Open$1.14 Day$1.09–1.15 52W close$0.82–1.58 Avg vol 30d56K Short int388K · 2.0% float · 14.2d Short vol16% DataOct 2022–Aug 2026 Filing10-Q · Aug 13

Raw chart and full-history price indicators begin at the captured split on Oct 11, 2022; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +1%
above
Price vs 50-day avg +10%
above
RSI (14) 61
neutral
MACD trend Positive
52-week position 36%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +17%
trailing
6-month return +9%
trailing
YTD return +11%
this year
Relative strength −5%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+8% holders QoQ · +7 funds added
Insider flow Accumulating
Net +$80.4K over 90 days · 0% sells
Short interest Falling
2.01% of float · ▼ -1.8% MoM · 14.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
28 holders — mid 3-yr range
Squeeze score 65
elevated · 0–100
Fundamentals
Fair
Gross margin 57%
EPS growth +55%
Y/Y
Free cash flow $-8.2M
Balance sheet $42.9M
net debt
Quant / Vol
risk profile
Very High
Volatility 78%
annualized · 1-yr
Max drawdown −52%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+1% Bullish
Price vs 50-day avg
+10% Bullish
RSI (14)
61 Neutral
MACD trend
Positive Bullish
52-week position
36% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+8% holders QoQ · +7 funds added
Insider flow Accumulating
Net +$80.4K over 90 days · 0% sells
Short interest Falling
2.01% of float · ▼ -1.8% MoM · 14.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
28 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 36% Range high $2
vs 200-day avg +1% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
COCP
Cocrystal Pharma, Inc.
this stock
$21.38M +11.2% -69.3% — 2.0%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +17.5% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
28
% held
5.8%
Net QoQ
+335.9K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Falling
Shares short
388.0K
Days to cover
14.2d
Change
-7.0K sh
View
Short Volume
Short vol %
16%
As of
Aug 17, 2026
Short Total
View
Fails to Deliver
FTD shares
1.3K
Value
$1.1K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
66.5%
Week of
Jul 13, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$80.4K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$2.0M
Net income (FY)
$-8.8M
EPS diluted
$-0.78
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 17, 2026
This year
17
View

Performance

Raw-price comparisons begin at the captured split on Oct 11, 2022; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
COCP +0.9% +17.2% +9.0% +32.9% +11.2%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY +0.5% +12.8% -4.8% +29.0% -2.6%
Key facts CIK 1412486 CUSIP 19188J409 13F (30d) 29 filings 29 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)